


WHAT IS CLAIMED IS:

1. Use of an effective amount of a compound of Formula (A), or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating amyloidosis, wherein:

the compound of Formula (A) has the structure:



wherein:

R¹ is selected from the group consisting of hydrogen, halogen, a substituted or unsubstituted C₁-C₆ alkyl, a substituted or unsubstituted C₁-C₆ haloalkyl, a substituted or unsubstituted C₃-C₆ cycloalkyl, a substituted or unsubstituted C₁-C₆ alkoxy, an unsubstituted mono-C₁-C₆ alkylamine and an unsubstituted di-C₁-C₆ alkylamine;

each R² is independently selected from the group consisting of halogen, a substituted or unsubstituted C₁-C₆ alkyl, a substituted or unsubstituted C₁-C₆ haloalkyl and a substituted or unsubstituted C₃-C₆ cycloalkyl; or

when m is 2 or 3, each R² is independently selected from the group consisting of halogen, a substituted or unsubstituted C₁-C₆ alkyl, a substituted or unsubstituted C₁-C₆ haloalkyl and a substituted or unsubstituted C₃-C₆ cycloalkyl, or two R² groups taken together with the atom(s) to which they are attached form a substituted or unsubstituted C₃-C₆ cycloalkyl or a substituted or unsubstituted 3 to 6 membered heterocyclyl;

R^4 is selected from the group consisting of NO_2 , $\text{S}(\text{O})\text{R}^6$, SO_2R^6 , halogen, cyano and an unsubstituted $\text{C}_1\text{-C}_6$ haloalkyl;

R^5 is $-\text{X}^1-(\text{Alk}^1)_n-\text{R}^7$;

Alk^1 is selected from an unsubstituted $\text{C}_1\text{-C}_4$ alkylene and a $\text{C}_1\text{-C}_4$ alkylene substituted with 1, 2 or 3 substituents independently selected from fluoro, chloro, an unsubstituted $\text{C}_1\text{-C}_3$ alkyl and an unsubstituted $\text{C}_1\text{-C}_3$ haloalkyl;

R^6 is selected from the group consisting of a substituted or unsubstituted $\text{C}_1\text{-C}_6$ alkyl, a substituted or unsubstituted $\text{C}_1\text{-C}_6$ haloalkyl and a substituted or unsubstituted $\text{C}_3\text{-C}_6$ cycloalkyl;


R^7 is selected from a substituted or unsubstituted $\text{C}_1\text{-C}_6$ alkoxy, a substituted or unsubstituted $\text{C}_3\text{-C}_{10}$ cycloalkyl, a substituted or unsubstituted 3 to 10 membered heterocyclyl, hydroxy, amino, a substituted or unsubstituted mono-substituted amine group, a substituted or unsubstituted di-substituted amine group, a substituted or unsubstituted N-carbamyl, a substituted or unsubstituted C-amido and a substituted or unsubstituted N-amido;

m is 0, 1, 2 or 3;

n is selected from the group consisting of 0 and 1; and

X^1 is selected from the group consisting of $-\text{O}-$, $-\text{S}-$ and $-\text{NH}-$.

2. The use of Claim 1, wherein the compound of Formula (A) is




3. The use of Claim 2, wherein R^1 is hydrogen.







4. The use of Claim 2, wherein R^1 is halogen.







5. The use of Claim 2, wherein R^1 is an unsubstituted C_1 - C_6 alkyl.
6. The use of Claim 2, wherein R^1 is an unsubstituted C_1 - C_6 haloalkyl.
7. The use of Claim 6, wherein R^1 is $-\text{CHF}_2$, $-\text{CF}_3$, $-\text{CH}_2\text{CF}_3$ or $-\text{CF}_2\text{CH}_3$.
8. The use of any one of Claims 1-7, wherein m is 2.
9. The use of any one of Claims 2-8, wherein each R^2 is an unsubstituted C_1 - C_6 alkyl.
10. The use of any one of Claims 2-8, wherein two R^2 groups taken together with the atom(s) to which they are attached form an unsubstituted C_3 - C_6 cycloalkyl.
11. The use of any one of Claims 2-10, wherein R^4 is NO_2 .
12. The use of any one of Claims 2-11, wherein R^5 is $-\text{X}^1-(\text{Alk}^1)_n-\text{R}^7$; wherein X^1 is $-\text{NH}-$; n is 0; Alk^1 is an unsubstituted C_1 - C_4 alkylene; and R^7 is a substituted or unsubstituted 3 to 10 membered heterocyclyl.
13. The use of any one of Claims 2-11, wherein R^5 is $-\text{X}^1-(\text{Alk}^1)_n-\text{R}^7$; wherein X^1 is $-\text{NH}-$; n is 1; Alk^1 is an unsubstituted C_1 - C_4 alkylene; and R^7 is a substituted or unsubstituted 3 to 10 membered heterocyclyl.
14. The use of any one of Claims 2-11, wherein R^5 is $-\text{X}^1-(\text{Alk}^1)_n-\text{R}^7$; wherein X^1 is $-\text{O}-$; n is 0; Alk^1 is an unsubstituted C_1 - C_4 alkylene; and R^7 is a substituted or unsubstituted 3 to 10 membered heterocyclyl.
15. The use of any one of Claims 2-11, wherein R^5 is $-\text{X}^1-(\text{Alk}^1)_n-\text{R}^7$; wherein X^1 is $-\text{O}-$; n is 1; Alk^1 is an unsubstituted C_1 - C_4 alkylene; and R^7 is a substituted or unsubstituted 3 to 10 membered heterocyclyl.
16. The use of any one of Claims 12-15, wherein R^7 is a substituted or unsubstituted 3 to 6 membered monocyclic heterocyclyl.
17. The use of any one of Claims 12-15, wherein R^7 is a substituted or unsubstituted 6 to 10 membered spiro heterocyclyl.
18. The use of any one of Claims 12-17, wherein R^7 is unsubstituted.
19. The use of any one of Claims 12-17, wherein R^7 is substituted with 1 or 2 substituents independently selected from the group consisting of an







unsubstituted C₁-C₆ alkyl, an unsubstituted C₁-C₆ alkoxy, fluoro, chloro, hydroxy and -SO₂-(unsubstituted C₁-C₆ alkyl).







20. The use of Claim 1, wherein the compound of Formula (A) is selected from the group consisting of:
















































and

, or a


pharmaceutically acceptable salt of any of the foregoing.

21. The use of Claim 20, wherein the compound of Formula (A) is




, or a pharmaceutically acceptable salt thereof.

22. The use of Claim 20, wherein the compound of Formula (A) is




, or a pharmaceutically acceptable salt thereof.

23. The use of Claim 20, wherein the compound of Formula (A) is




, or a pharmaceutically acceptable salt thereof.

24. The use of Claim 20, wherein the compound of Formula (A) is



, or a pharmaceutically acceptable salt thereof.

25. The use of Claim 20, wherein the compound of Formula (A) is



, or a pharmaceutically acceptable salt thereof.

26. The use of any one of Claims 1-25, wherein the compound of Formula (A) is used in a combination of compounds, wherein the combination of compounds comprises an effective amount of one or more of Compound (B), or a

pharmaceutically acceptable salt thereof, and wherein the one or more of Compound (B) is a corticosteroid, a proteasome inhibitor, or a pharmaceutically acceptable salt of any of the foregoing.

27. The use of Claim 26, wherein the corticosteroid is selected from the group consisting of hydrocortisone, hydrocortisone acetate, cortisone acetate, tixocortol pivalate, prednisolone, methylprednisolone, prednisone, beclometasone, betamethasone, dexamethasone, fluocortolone, halometasone, mometasone, Amcinonide, budesonide, desonide, fluocinolone acetonide, fluocinonide, halcinonide, triamcinolone acetonide, alclometasone dipropionate, betamethasone dipropionate, betamethasone valerate, clobetasol propionate, clobetasone butyrate, fluprednidene acetate, mometasone furoate, ciclesonide, cortisone acetate, hydrocortisone aceponate, hydrocortisone acetate, hydrocortisone buteprate, hydrocortisone butyrate, hydrocortisone valerate, prednicarbate, tixocortol pivalate, and a pharmaceutically acceptable salt of any of the foregoing.

28. The use of Claim 26 or 27, wherein the proteasome inhibitor is selected from the group consisting of bortezomib, carfilzomib, ixazomib, a pharmaceutically acceptable salt of any of the foregoing, and combinations thereof.

29. The use of any one of Claims 1-28, wherein the amyloidosis is selected from the group consisting of amyloid light-chain (AL) amyloidosis, amyloid type A (AA) amyloidosis, dialysis-related amyloidosis (DRA), familial or hereditary amyloidosis, age-related (senile) systemic amyloidosis, organ-specific amyloidosis and combinations thereof.

30. The use of Claim 29, wherein the disease or condition is AL amyloidosis.